

## **Karolinska Development's portfolio company OssDsign completes patient enrolment to the TOP FUSION study**

STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery.

OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company's nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021.

"OssDsign builds a comprehensive package of clinical data for OssDsign Catalyst, now with a fully recruited TOP FUSION study. The study will generate important clinical information that paves the way for establishing the product in the global market," says Viktor Drvota, CEO, Karolinska Development.

Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4 percent.

### **For further information, please contact:**

Viktor Drvota, CEO, Karolinska Development AB  
Phone: +46 73 982 52 02, e-mail: viktor.dravota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB  
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

### **TO THE EDITORS**

#### **About Karolinska Development AB**

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit [www.karolinskadevelopment.com](http://www.karolinskadevelopment.com).